Therapeutic peptides: New arsenal against drug resistant pathogens

Current Pharmaceutical Design

Volumn 20, Issue 5, 2014, Pages 771-792

  Mok, Wendy W K ^a,c   Li, Yingfu ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c Princeton University   (United States)

Author keywords

Cationic antimicrobial peptides; Host defense peptides; Peptide therapeutics; Peptidomimetics

Indexed keywords

ANTITOXIN; AP 214; AP 405; BETA DEFENSIN; BRILACIDIN; CARDIOLIPIN; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CLS 001; DELMITIDE; DIAPEP 277; DRUG CARRIER; EA 230; GHRELIN; HB 107; HB 1275; HB 1345; HLF 1 11; HOST DEFENSE PEPTIDE; IMX 942; ISEGANAN; LACTOFERRIN; LANTIBIOTIC; LIPID A; LIPOTEICHOIC ACID; LTX 109; MAGAININ 2; MB 226; MONOMER; MX 226; OLIGOMER; OMIGANAN; OP 145; OPEBACAN; PAC 113; PEPTIDE DERIVATIVE; PEXIGANAN; PHOSPHATIDYLGLYCEROL; PLECTASIN; POLYMYXIN B; POLYPEPTIDE ANTIBIOTIC AGENT; PROTAMINE SULFATE; PTX 005; SIDEROPHORE; SYNTHETIC PEPTIDE; TOBRAMYCIN; TOXIN; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; XOMA 629;

AMINO ACID SUBSTITUTION; ANTIMICROBIAL ACTIVITY; BACILLUS CEREUS; CELL DEATH; CELL KILLING; CELL MEMBRANE; DNA SYNTHESIS; DRUG DELIVERY SYSTEM; DRUG DESIGN; ENTEROCOCCUS FAECALIS; GENOME; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNOMODULATION; KLEBSIELLA PNEUMONIAE; LISTERIA MONOCYTOGENES; MEMBRANE DAMAGE; MEMBRANE PERMEABILITY; MYCOBACTERIUM TUBERCULOSIS; NEISSERIA GONORRHOEAE; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN SYNTHESIS; PSEUDOMONAS PNEUMONIA; REVIEW; RNA SYNTHESIS; STAPHYLOCOCCUS AUREUS; STATIC ELECTRICITY; SURFACE CHARGE; XENORHABDUS NEMATOPHILA;

ANIMALS; ANTI-INFECTIVE AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; CELL MEMBRANE PERMEABILITY; DRUG DESIGN; DRUG RESISTANCE, MULTIPLE; DRUGS, INVESTIGATIONAL; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNOMODULATION; INFECTION; LIPID BILAYERS; MEMBRANE TRANSPORT MODULATORS; PEPTIDE FRAGMENTS; PEPTIDES; PROTEIN CONFORMATION; RECOMBINANT PROTEINS;

EID: 84895126021     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990011     Document Type: Review

References (223)

1. Fauci AS. Infectious diseases: considerations for the 21st century. Clin Infect Dis 2001; 32(5): 675-85.
2. Davies J. Where have All the Antibiotics Gone? Can J Infect Dis Med Microbiol 2006; 17(5): 287-90.
3. Klein E, Smith DL, Laxminarayan R. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005. Emerg Infect Dis 2007; 13(12): 1840-6.
4. Levy SB, Marshall B. Antibacterial resistance worldwide: causes, challenges and responses. Nat Med 2004; 10(12 Suppl): S122-9.
5. Wright GD. The antibiotic resistome: the nexus of chemical and genetic diversity. Nat Rev Microbiol 2007; 5(3): 175-86.
6. Projan SJ. Why is big Pharma getting out of antibacterial drug discovery? Curr Opin Microbiol 2003; 6(5): 427-30.
7. Bush K, Courvalin P, Dantas G, et al. Tackling antibiotic resistance. Nat Rev Microbiol 2011; 9(12): 894-6.
8. Hancock RE, Sahl HG. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol 2006; 24(12): 1551-7.
9. Wang G, Li X, Wang Z. APD2: the updated antimicrobial peptide database and its application in peptide design. Nucleic Acids Res 2009; 37(Database issue): D933-7.
10. Seshadri Sundararajan V, Gabere MN, Pretorius A, et al. DAMPD: a manually curated antimicrobial peptide database. Nucleic Acids Res 2012; 40(Database issue): D1108-12.
11. Wang G, Li, X., and Zasloff, M. A database view of naturally occurring antimicrobial peptides: Discovery, nomenclature, classfication and amino acid sequence analysis. In: Wang G, editor. Antimicrobial Peptides: Discovery, Design and Novel Therapeutic Strategies. Wallingford, Oxfordshire: CAB International 2010. p. 1-21.
12. Troxler RF, Offner GD, Xu T, Vanderspek JC, Oppenheim FG. Structural relationship between human salivary histatins. J Dent Res 1990; 69(1): 2-6.
13. Valore EV, Park CH, Quayle AJ, Wiles KR, McCray PB, Jr., Ganz T. Human beta-defensin-1: an antimicrobial peptide of urogenital tissues. J Clin Invest 1998; 101(8): 1633-42.
14. Devine DA, Hancock RE. Cationic peptides: distribution and mechanisms of resistance. Curr Pharm Des 2002; 8(9): 703-14.
15. Schutte BC, Mitros JP, Bartlett JA, et al. Discovery of five conserved beta-defensin gene clusters using a computational search strategy. Proc Natl Acad Sci U S A 2002; 99(4): 2129-33.
16. Fjell CD, Hancock RE, Cherkasov A. AMPer: a database and an automated discovery tool for antimicrobial peptides. Bioinformatics 2007; 23(9): 1148-55.
17. Sawyer JG, Martin NL, Hancock RE. Interaction of macrophage cationic proteins with the outer membrane of Pseudomonas aeruginosa. Infect Immun 1988; 56(3): 693-8.
18. Hancock RE, Chapple DS. Peptide antibiotics. Antimicrob Agents Chemother 1999; 43(6): 1317-23.
19. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature 2002; 415(6870): 389-95.
20. Wimley WC, Hristova K. Antimicrobial peptides: successes, challenges and unanswered questions. J Membr Biol 2011; 239(1-2): 27-34.
21. Rapaport D, Shai Y. Interaction of fluorescently labeled pardaxin and its analogues with lipid bilayers. J Biol Chem 1991; 266(35): 23769-75.
22. Baumann G, Mueller P. A molecular model of membrane excitability. J Supramol Struct 1974; 2(5-6): 538-57.
23. Ludtke SJ, He K, Heller WT, Harroun TA, Yang L, Huang HW. Membrane pores induced by magainin. Biochemistry 1996; 35(43): 13723-8.
24. Matsuzaki K, Murase O, Fujii N, Miyajima K. An antimicrobial peptide, magainin 2, induced rapid flip-flop of phospholipids coupled with pore formation and peptide translocation. Biochemistry 1996; 35(35): 11361-8.
25. Pouny Y, Rapaport D, Mor A, Nicolas P, Shai Y. Interaction of antimicrobial dermaseptin and its fluorescently labeled analogues with phospholipid membranes. Biochemistry 1992; 31(49): 12416-23.
26. Shai Y, Oren Z. From carpet mechanism to de-novo designed diastereomeric cell-selective antimicrobial peptides. Peptides 2001; 22(10): 1629-41.
27. Epand RM, Epand RF. Bacterial membrane lipids in the action of antimicrobial agents. J Pept Sci 2011; 17(5): 298-305.
28. Bechinger B, Lohner K. Detergent-like actions of linear amphipathic cationic antimicrobial peptides. Biochim Biophys Acta 2006; 1758(9): 1529-39.
29. Henzler Wildman KA, Lee DK, Ramamoorthy A. Mechanism of lipid bilayer disruption by the human antimicrobial peptide, LL-37. Biochemistry 2003; 42(21): 6545-58.
30. Neville F, Cahuzac M, Konovalov O, et al. Lipid headgroup discrimination by antimicrobial peptide LL-37: insight into mechanism of action. Biophys J 2006; 90(4): 1275-87.
31. Wilmes M, Cammue BP, Sahl HG, Thevissen K. Antibiotic activities of host defense peptides: more to it than lipid bilayer perturbation. Nat Prod Rep 2011; 28(8): 1350-8.
32. Brogden KA. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat Rev Microbiol 2005; 3(3): 238-50.
33. Hsu CH, Chen C, Jou ML, et al. Structural and DNA-binding studies on the bovine antimicrobial peptide, indolicidin: evidence for multiple conformations involved in binding to membranes and DNA. Nucleic Acids Res 2005; 33(13): 4053-64.
34. Patrzykat A, Friedrich CL, Zhang L, Mendoza V, Hancock RE. Sublethal concentrations of pleurocidin-derived antimicrobial peptides inhibit macromolecular synthesis in Escherichia coli. Antimicrob Agents Chemother 2002; 46(3): 605-14.
35. Xiong YQ, Bayer AS, Yeaman MR. Inhibition of intracellular macromolecular synthesis in Staphylococcus aureus by thrombininduced platelet microbicidal proteins. J Infect Dis 2002; 185(3): 348-56.
36. Park CB, Kim MS, Kim SC. A novel antimicrobial peptide from Bufo bufo gargarizans. Biochem Biophys Res Commun 1996; 218(1): 408-13.
37. Schneider T, Kruse T, Wimmer R, et al. Plectasin, a fungal defensin, targets the bacterial cell wall precursor Lipid II. Science 2010; 328(5982): 1168-72.
38. Thevissen K, Francois IE, Takemoto JY, Ferket KK, Meert EM, Cammue BP. DmAMP1, an antifungal plant defensin from dahlia (Dahlia merckii), interacts with sphingolipids from Saccharomyces cerevisiae. FEMS Microbiol Lett 2003; 226(1): 169-73.
39. Thevissen K, Warnecke DC, Francois IE, et al. Defensins from insects and plants interact with fungal glucosylceramides. J Biol Chem 2004; 279(6): 3900-5.
40. Thevissen K, Kristensen HH, Thomma BP, Cammue BP, Francois IE. Therapeutic potential of antifungal plant and insect defensins. Drug Discov Today 2007; 12(21-22): 966-71.
41. Easton DM, Nijnik A, Mayer ML, Hancock RE. Potential of immunomodulatory host defense peptides as novel anti-infectives. Trends Biotechnol 2009; 27(10): 582-90.
42. Mookherjee N, Brown KL, Bowdish DM, et al. Modulation of the TLR-mediated inflammatory response by the endogenous human host defense peptide LL-37. J Immunol 2006; 176(4): 2455-64.
43. Zughaier SM, Shafer WM, Stephens DS. Antimicrobial peptides and endotoxin inhibit cytokine and nitric oxide release but amplify respiratory burst response in human and murine macrophages. Cell Microbiol 2005; 7(9): 1251-62.
44. Scott MG, Dullaghan E, Mookherjee N, et al. An anti-infective peptide that selectively modulates the innate immune response. Nat Biotechnol 2007; 25(4): 465-72.
45. Davidson DJ, Currie AJ, Reid GS, et al. The cationic antimicrobial peptide LL-37 modulates dendritic cell differentiation and dendritic cell-induced T cell polarization. J Immunol 2004; 172(2): 1146-56.
46. Territo MC, Ganz T, Selsted ME, Lehrer R. Monocyte-chemotactic activity of defensins from human neutrophils. J Clin Invest 1989; 84(6): 2017-20.
47. Steinstraesser L, Koehler T, Jacobsen F, et al. Host defense peptides in wound healing. Mol Med 2008; 14(7-8): 528-37.
48. Lau YE, Bowdish DM, Cosseau C, Hancock RE, Davidson DJ. Apoptosis of airway epithelial cells: human serum sensitive induction by the cathelicidin LL-37. Am J Respir Cell Mol Biol 2006; 34(4): 399-409.
49. Rosenfeld Y, Papo N, Shai Y. Endotoxin (lipopolysaccharide) neutralization by innate immunity host-defense peptides. Peptide properties and plausible modes of action. J Biol Chem 2006; 281(3): 1636-43.
50. Rosenfeld Y, Sahl HG, Shai Y. Parameters involved in antimicrobial and endotoxin detoxification activities of antimicrobial peptides. Biochemistry 2008; 47(24): 6468-78.
51. Bowdish DM, Hancock RE. Anti-endotoxin properties of cationic host defence peptides and proteins. J Endotoxin Res 2005; 11(4): 230-6.
52. Chamorro CI, Weber G, Gronberg A, Pivarcsi A, Stahle M. The human antimicrobial peptide LL-37 suppresses apoptosis in keratinocytes. J Invest Dermatol 2009; 129(4): 937-44.
53. Otte JM, Zdebik AE, Brand S, et al. Effects of the cathelicidin LL-37 on intestinal epithelial barrier integrity. Regul Pept 2009; 156(1-3): 104-17.
54. Kim HJ, Cho DH, Lee KJ, et al. LL-37 suppresses sodium nitroprusside-induced apoptosis of systemic sclerosis dermal fibroblasts. Exp Dermatol 2011; 20(10): 843-5.
55. Ciornei CD, Tapper H, Bjartell A, Sternby NH, Bodelsson M. Human antimicrobial peptide LL-37 is present in atherosclerotic plaques and induces death of vascular smooth muscle cells: a laboratory study. BMC Cardiovasc Disord 2006; 6: 49.
56. Scott MG, Davidson DJ, Gold MR, Bowdish D, Hancock RE. The human antimicrobial peptide LL-37 is a multifunctional modulator of innate immune responses. J Immunol 2002; 169(7): 3883-91.
57. Jonsson D, Nilsson BO. The antimicrobial peptide LL-37 is antiinflammatory and proapoptotic in human periodontal ligament cells. J Periodontal Res 2011.
58. Varkey J, Nagaraj R. Antibacterial activity of human neutrophil defensin HNP-1 analogs without cysteines. Antimicrob Agents Chemother 2005; 49(11): 4561-6.
59. Edgerton M, Koshlukova SE, Araujo MW, Patel RC, Dong J, Bruenn JA. Salivary histatin 5 and human neutrophil defensin 1 kill Candida albicans via shared pathways. Antimicrob Agents Chemother 2000; 44(12): 3310-6.
60. Salvatore M, Garcia-Sastre A, Ruchala P, Lehrer RI, Chang T, Klotman ME. alpha-Defensin inhibits influenza virus replication by cell-mediated mechanism(s). J Infect Dis 2007; 196(6): 835-43.
61. Dugan AS, Maginnis MS, Jordan JA, et al. Human alpha-defensins inhibit BK virus infection by aggregating virions and blocking binding to host cells. J Biol Chem 2008; 283(45): 31125-32.
62. Bastian A, Schafer H. Human alpha-defensin 1 (HNP-1) inhibits adenoviral infection in vitro. Regul Pept 2001; 101(1-3): 157-61.
63. Travis SM, Anderson NN, Forsyth WR, et al. Bactericidal activity of mammalian cathelicidin-derived peptides. Infect Immun 2000; 68(5): 2748-55.
64. Steinstraesser L, Kraneburg U, Jacobsen F, Al-Benna S. Host defense peptides and their antimicrobial-immunomodulatory duality. Immunobiology 2011; 216(3): 322-33.
65. Tew GN, Clements D, Tang H, Arnt L, Scott RW. Antimicrobial activity of an abiotic host defense peptide mimic. Biochim Biophys Acta 2006; 1758(9): 1387-92.
66. Marr AK, Gooderham WJ, Hancock RE. Antibacterial peptides for therapeutic use: obstacles and realistic outlook. Curr Opin Pharmacol 2006; 6(5): 468-72.
67. Koprivnjak T, Peschel A. Bacterial resistance mechanisms against host defense peptides. Cell Mol Life Sci 2011; 68(13): 2243-54.
68. Yeaman MR, Yount NY. Mechanisms of antimicrobial peptide action and resistance. Pharmacol Rev 2003; 55(1): 27-55.
69. Campos MA, Vargas MA, Regueiro V, Llompart CM, Alberti S, Bengoechea JA. Capsule polysaccharide mediates bacterial resistance to antimicrobial peptides. Infect Immun 2004; 72(12): 7107-14.
70. Belland RJ, Trust TJ. Synthesis, export, and assembly of Aeromonas salmonicida A-layer analyzed by transposon mutagenesis. J Bacteriol 1985; 163(3): 877-81.
71. Henry MA, Secombes CJ. The A-layer influences the susceptibility of Aeromonas salmonicida to antibacterial peptides. Fish Shellfish Immunol 2000; 10(7): 637-42.
72. Perea Velez M, Verhoeven TL, Draing C, et al. Functional analysis of D-alanylation of lipoteichoic acid in the probiotic strain Lactobacillus rhamnosus GG. Appl Environ Microbiol 2007; 73(11): 3595-604.
73. Gunn JS, Lim KB, Krueger J, et al. PmrA-PmrB-regulated genes necessary for 4-aminoarabinose lipid A modification and polymyxin resistance. Mol Microbiol 1998; 27(6): 1171-82.
74. Guo L, Lim KB, Poduje CM, et al. Lipid A acylation and bacterial resistance against vertebrate antimicrobial peptides. Cell 1998; 95(2): 189-98.
75. Clauditz A, Resch A, Wieland KP, Peschel A, Gotz F. Staphyloxanthin plays a role in the fitness of Staphylococcus aureus and its ability to cope with oxidative stress. Infect Immun 2006; 74(8): 4950-3.
76. Mishra NN, Liu GY, Yeaman MR, et al. Carotenoid-related alteration of cell membrane fluidity impacts Staphylococcus aureus susceptibility to host defense peptides. Antimicrob Agents Chemother 2011; 55(2): 526-31.
77. Bayer AS, Prasad R, Chandra J, et al. In vitro resistance of Staphylococcus aureus to thrombin-induced platelet microbicidal protein is associated with alterations in cytoplasmic membrane fluidity. Infect Immun 2000; 68(6): 3548-53.
78. Staubitz P, Neumann H, Schneider T, Wiedemann I, Peschel A. MprF-mediated biosynthesis of lysylphosphatidylglycerol, an important determinant in staphylococcal defensin resistance. FEMS Microbiol Lett 2004; 231(1): 67-71.
79. Weidenmaier C, Kristian SA, Peschel A. Bacterial resistance to antimicrobial host defenses--an emerging target for novel antiinfective strategies? Curr Drug Targets 2003; 4(8): 643-9.
80. Ernst CM, Staubitz P, Mishra NN, et al. The bacterial defensin resistance protein MprF consists of separable domains for lipid lysinylation and antimicrobial peptide repulsion. PLoS Pathog 2009; 5(11): e1000660.
81. Jin T, Bokarewa M, Foster T, Mitchell J, Higgins J, Tarkowski A. Staphylococcus aureus resists human defensins by production of staphylokinase, a novel bacterial evasion mechanism. J Immunol 2004; 172(2): 1169-76.
82. Shafer WM, Qu X, Waring AJ, Lehrer RI. Modulation of Neisseria gonorrhoeae susceptibility to vertebrate antibacterial peptides due to a member of the resistance/nodulation/division efflux pump family. Proc Natl Acad Sci U S A 1998; 95(4): 1829-33.
83. Sieprawska-Lupa M, Mydel P, Krawczyk K, et al. Degradation of human antimicrobial peptide LL-37 by Staphylococcus aureus-derived proteinases. Antimicrob Agents Chemother 2004; 48(12): 4673-9.
84. von Pawel-Rammingen U, Bjorck L. IdeS and SpeB: immunoglobulin-degrading cysteine proteinases of Streptococcus pyogenes. Curr Opin Microbiol 2003; 6(1): 50-5.
85. Schmidtchen A, Frick IM, Andersson E, Tapper H, Bjorck L. Proteinases of common pathogenic bacteria degrade and inactivate the antibacterial peptide LL-37. Mol Microbiol 2002; 46(1): 157-68.
86. Guina T, Yi EC, Wang H, Hackett M, Miller SI. A PhoP-regulated outer membrane protease of Salmonella enterica serovar typhimurium promotes resistance to alpha-helical antimicrobial peptides. J Bacteriol 2000; 182(14): 4077-86.
87. Stumpe S, Schmid R, Stephens DL, Georgiou G, Bakker EP. Identification of OmpT as the protease that hydrolyzes the antimicrobial peptide protamine before it enters growing cells of Escherichia coli. J Bacteriol 1998; 180(15): 4002-6.
88. Galvan EM, Lasaro MA, Schifferli DM. Capsular antigen fraction 1 and Pla modulate the susceptibility of Yersinia pestis to pulmonary antimicrobial peptides such as cathelicidin. Infect Immun 2008; 76(4): 1456-64.
89. Bessalle R, Haas H, Goria A, Shalit I, Fridkin M. Augmentation of the antibacterial activity of magainin by positive-charge chain extension. Antimicrob Agents Chemother 1992; 36(2): 313-7.
90. Pal T, Sonnevend A, Galadari S, Conlon JM. Design of potent, non-toxic antimicrobial agents based upon the structure of the frog skin peptide, pseudin-2. Regul Pept 2005; 129(1-3): 85-91.
91. Conlon JM, Sonnevend, Agnes. Clinical Applications of Amphibian Antimicrobial Peptides. Journal of Medical Sciences 2011; 4(2): 62-72.
92. Stark M, Liu LP, Deber CM. Cationic hydrophobic peptides with antimicrobial activity. Antimicrob Agents Chemother 2002; 46(11): 3585-90.
93. Glukhov E, Stark M, Burrows LL, Deber CM. Basis for selectivity of cationic antimicrobial peptides for bacterial versus mammalian membranes. J Biol Chem 2005; 280(40): 33960-7.
94. Burrows LL, Stark M, Chan C, Glukhov E, Sinnadurai S, Deber CM. Activity of novel non-amphipathic cationic antimicrobial peptides against Candida species. J Antimicrob Chemother 2006; 57(5): 899-907.
95. Yin LM, Edwards MA, Li J, Yip CM, Deber CM. Roles of Hydrophobicity and Charge Distribution of Cationic Antimicrobial Peptides in Peptide-Membrane Interactions. J Biol Chem 2012.
96. Hilpert K, Volkmer-Engert R, Walter T, Hancock RE. High-throughput generation of small antibacterial peptides with improved activity. Nat Biotechnol 2005; 23(8): 1008-12.
97. Hilpert K, Hancock RE. Use of luminescent bacteria for rapid screening and characterization of short cationic antimicrobial peptides synthesized on cellulose using peptide array technology. Nat Protoc 2007; 2(7): 1652-60.
98. Loose C, Jensen K, Rigoutsos I, Stephanopoulos G. A linguistic model for the rational design of antimicrobial peptides. Nature 2006; 443(7113): 867-9.
99. Wang Z, Wang G. APD: the Antimicrobial Peptide Database. Nucleic Acids Res 2004; 32(Database issue): D590-2.
100. Khandelia H, Langham AA, Kaznessis YN. Driving engineering of novel antimicrobial peptides from simulations of peptide-micelle interactions. Biochim Biophys Acta 2006; 1758(9): 1224-34.
101. Langham AA, Khandelia H, Schuster B, Waring AJ, Lehrer RI, Kaznessis YN. Correlation between simulated physicochemical properties and hemolycity of protegrin-like antimicrobial peptides: predicting experimental toxicity. Peptides 2008; 29(7): 1085-93.
102. Fjell CD, Jenssen H, Hilpert K, et al. Identification of novel antibacterial peptides by chemoinformatics and machine learning. J Med Chem 2009; 52(7): 2006-15.
103. Cherkasov A, Hilpert K, Jenssen H, et al. Use of artificial intelligence in the design of small peptide antibiotics effective against a broad spectrum of highly antibiotic-resistant superbugs. ACS Chem Biol 2009; 4(1): 65-74.
104. Fjell CD, Jenssen H, Cheung WA, Hancock RE, Cherkasov A. Optimization of antibacterial peptides by genetic algorithms and cheminformatics. Chem Biol Drug Des 2011; 77(1): 48-56.
105. Fjell CD, Hiss JA, Hancock RE, Schneider G. Designing antimicrobial peptides: form follows function. Nat Rev Drug Discov 2011; 11(1): 37-51.
106. Bessalle R, Kapitkovsky A, Gorea A, Shalit I, Fridkin M. All-Dmagainin: chirality, antimicrobial activity and proteolytic resistance. FEBS Lett 1990; 274(1-2): 151-5.
107. Wade D, Boman A, Wahlin B, et al. All-D amino acid-containing channel-forming antibiotic peptides. Proc Natl Acad Sci U S A 1990; 87(12): 4761-5.
108. Hamamoto K, Kida Y, Zhang Y, Shimizu T, Kuwano K. Antimicrobial activity and stability to proteolysis of small linear cationic peptides with D-amino acid substitutions. Microbiol Immunol 2002; 46(11): 741-9.
109. Dathe M, Schumann M, Wieprecht T, et al. Peptide helicity and membrane surface charge modulate the balance of electrostatic and hydrophobic interactions with lipid bilayers and biological membranes. Biochemistry 1996; 35(38): 12612-22.
110. Meng H, Kumar K. Antimicrobial activity and protease stability of peptides containing fluorinated amino acids. J Am Chem Soc 2007; 129(50): 15615-22.
111. Radzishevsky IS, Rotem S, Zaknoon F, Gaidukov L, Dagan A, Mor A. Effects of acyl versus aminoacyl conjugation on the properties of antimicrobial peptides. Antimicrob Agents Chemother 2005; 49(6): 2412-20.
112. Shalev DE, Rotem S, Fish A, Mor A. Consequences of N-acylation on structure and membrane binding properties of dermaseptin derivative K4-S4-(1-13). J Biol Chem 2006; 281(14): 9432-8.
113. Peschel A, Sahl HG. The co-evolution of host cationic antimicrobial peptides and microbial resistance. Nat Rev Microbiol 2006; 4(7): 529-36.
114. Nguyen LT, Chau JK, Perry NA, de Boer L, Zaat SA, Vogel HJ. Serum stabilities of short tryptophan-and arginine-rich antimicrobial peptide analogs. PLoS One 2010; 5(9).
115. Otvos L, Jr., Bokonyi K, Varga I, et al. Insect peptides with improved protease-resistance protect mice against bacterial infection. Protein Sci 2000; 9(4): 742-9.
116. Li X, Li Y, Han H, Miller DW, Wang G. Solution structures of human LL-37 fragments and NMR-based identification of a minimal membrane-targeting antimicrobial and anticancer region. J Am Chem Soc 2006; 128(17): 5776-85.
117. Tew GN, Liu D, Chen B, et al. De novo design of biomimetic antimicrobial polymers. Proc Natl Acad Sci U S A 2002; 99(8): 5110-4.
118. Claudon P, Violette A, Lamour K, et al. Consequences of isostructural main-chain modifications for the design of antimicrobial foldamers: helical mimics of host-defense peptides based on a heterogeneous amide/urea backbone. Angew Chem Int Ed Engl 2010; 49(2): 333-6.
119. Mowery BP, Lee SE, Kissounko DA, et al. Mimicry of antimicrobial host-defense peptides by random copolymers. J Am Chem Soc 2007; 129(50): 15474-6.
120. Epand RF, Mowery BP, Lee SE, et al. Dual mechanism of bacterial lethality for a cationic sequence-random copolymer that mimics host-defense antimicrobial peptides. J Mol Biol 2008; 379(1): 38-50.
121. Schmitt MA, Weisblum B, Gellman SH. Unexpected relationships between structure and function in alpha,beta-peptides: antimicrobial foldamers with heterogeneous backbones. J Am Chem Soc 2004; 126(22): 6848-9.
122. Yeung AT, Gellatly SL, Hancock RE. Multifunctional cationic host defence peptides and their clinical applications. Cell Mol Life Sci 2011; 68(13): 2161-76.
123. Zhang L, Falla TJ. Antimicrobial peptides: therapeutic potential. Expert Opin Pharmacother 2006; 7(6): 653-63.
124. Lamb HM, Wiseman LR. Pexiganan acetate. Drugs 1998; 56(6): 1047-52; discussion 53-4.
125. Ge Y, MacDonald DL, Holroyd KJ, Thornsberry C, Wexler H, Zasloff M. In vitro antibacterial properties of pexiganan, an analog of magainin. Antimicrob Agents Chemother 1999; 43(4): 782-8.
126. Moore A. The big and small of drug discovery. Biotech versus pharma: advantages and drawbacks in drug development. EMBO Rep 2003; 4(2): 114-7.
127. Lipsky BA, Holroyd KJ, Zasloff M. Topical versus systemic antimicrobial therapy for treating mildly infected diabetic foot ulcers: a randomized, controlled, double-blinded, multicenter trial of pexiganan cream. Clin Infect Dis 2008; 47(12): 1537-45.
128. Sader HS, Fedler KA, Rennie RP, Stevens S, Jones RN. Omiganan pentahydrochloride (MBI 226), a topical 12-amino-acid cationic peptide: spectrum of antimicrobial activity and measurements of bactericidal activity. Antimicrob Agents Chemother 2004; 48(8): 3112-8.
129. Anderegg TR, Fritsche TR, Jones RN. Quality control guidelines for MIC susceptibility testing of omiganan pentahydrochloride (MBI 226), a novel antimicrobial peptide. J Clin Microbiol 2004; 42(3): 1386-7.
130. Isaacson RE. MBI-226. Micrologix/Fujisawa. Curr Opin Investig Drugs 2003; 4(8): 999-1003.
131. Gordon YJ, Romanowski EG, McDermott AM. A review of antimicrobial peptides and their therapeutic potential as anti-infective drugs. Curr Eye Res 2005; 30(7): 505-15.
132. Butler MS. Natural products to drugs: natural product-derived compounds in clinical trials. Nat Prod Rep 2008; 25(3): 475-516.
133. Falla TJ, Zhang L. Efficacy of hexapeptide-7 on menopausal skin. J Drugs Dermatol 2010; 9(1): 49-54.
134. Zhang L, Falla TJ. Cosmeceuticals and peptides. Clin Dermatol 2009; 27(5): 485-94.
135. Kaser A, Tilg H. Novel therapeutic targets in the treatment of IBD. Expert Opin Ther Targets 2008; 12(5): 553-63.
136. Isaksson J, Brandsdal BO, Engqvist M, Flaten GE, Svendsen JS, Stensen W. A synthetic antimicrobial peptidomimetic (LTX 109): stereochemical impact on membrane disruption. J Med Chem 2011; 54(16): 5786-95.
137. Yount NY, Yeaman MR. Emerging themes and therapeutic prospects for anti-infective peptides. Annu Rev Pharmacol Toxicol 2012; 52: 337-60.
138. Kondejewski LH, Farmer SW, Wishart DS, Kay CM, Hancock RE, Hodges RS. Modulation of structure and antibacterial and hemolytic activity by ring size in cyclic gramicidin S analogs. J Biol Chem 1996; 271(41): 25261-8.
139. Ahmad I, Perkins WR, Lupan DM, Selsted ME, Janoff AS. Liposomal entrapment of the neutrophil-derived peptide indolicidin endows it with in vivo antifungal activity. Biochim Biophys Acta 1995; 1237(2): 109-14.
140. Schluesener HJ, Radermacher S, Melms A, Jung S. Leukocytic antimicrobial peptides kill autoimmune T cells. J Neuroimmunol 1993; 47(2): 199-202.
141. Welling MM, Lupetti A, Balter HS, et al. 99mTc-labeled antimicrobial peptides for detection of bacterial and Candida albicans infections. J Nucl Med 2001; 42(5): 788-94.
142. Welling MM, Paulusma-Annema A, Balter HS, Pauwels EK, Nibbering PH. Technetium-99m labelled antimicrobial peptides discriminate between bacterial infections and sterile inflammations. Eur J Nucl Med 2000; 27(3): 292-301.
143. Wang D, Kong L, Wang J, He X, Li X, Xiao Y. Polymyxin E sulfate-loaded liposome for intravenous use: preparation, lyophilization, and toxicity assessment in vivo. PDA J Pharm Sci Technol 2009; 63(2): 159-67.
144. Hussain R, Siligardi G. Novel drug delivery system for lipophilic therapeutics of small molecule, peptide-based and protein drugs. Chirality 2010; 22 Suppl 1: E44-6.
145. Hemm MR, Paul BJ, Miranda-Rios J, Zhang A, Soltanzad N, Storz G. Small stress response proteins in Escherichia coli: proteins missed by classical proteomic studies. J Bacteriol 2010; 192(1): 46-58.
146. Hemm MR, Paul BJ, Schneider TD, Storz G, Rudd KE. Small membrane proteins found by comparative genomics and ribosome binding site models. Mol Microbiol 2008; 70(6): 1487-501.
147. Yang YL, Xu Y, Straight P, Dorrestein PC. Translating metabolic exchange with imaging mass spectrometry. Nat Chem Biol 2009; 5(12): 885-7.
148. Hobbs EC, Fontaine F, Yin X, Storz G. An expanding universe of small proteins. Curr Opin Microbiol 2011; 14(2): 167-73.
149. Kolter R, Moreno F. Genetics of ribosomally synthesized peptide antibiotics. Annu Rev Microbiol 1992; 46: 141-63.
150. O'Connor EM, Shand RF. Halocins and sulfolobicins: the emerging story of archaeal protein and peptide antibiotics. J Ind Microbiol Biotechnol 2002; 28(1): 23-31.
151. de Jong A, van Hijum SA, Bijlsma JJ, Kok J, Kuipers OP. BAGEL: a web-based bacteriocin genome mining tool. Nucleic Acids Res 2006; 34(Web Server issue): W273-9.
152. de Jong A, van Heel AJ, Kok J, Kuipers OP. BAGEL2: mining for bacteriocins in genomic data. Nucleic Acids Res 2010; 38(Web Server issue): W647-51.
153. Hammami R, Zouhir A, Ben Hamida J, Fliss I. BACTIBASE: a new web-accessible database for bacteriocin characterization. BMC Microbiol 2007; 7: 89.
154. Hammami R, Zouhir A, Le Lay C, Ben Hamida J, Fliss I. BACTIBASE second release: a database and tool platform for bacteriocin characterization. BMC Microbiol 2010; 10: 22.
155. Cotter PD, Hill C, Ross RP. Bacteriocins: developing innate immunity for food. Nat Rev Microbiol 2005; 3(10): 777-88.
156. Siezen RJ, Kuipers OP, de Vos WM. Comparison of lantibiotic gene clusters and encoded proteins. Antonie Van Leeuwenhoek 1996; 69(2): 171-84.
157. Brotz H, Sahl HG. New insights into the mechanism of action of lantibiotics--diverse biological effects by binding to the same molecular target. J Antimicrob Chemother 2000; 46(1): 1-6.
158. Gut IM, Blanke SR, van der Donk WA. Mechanism of inhibition of Bacillus anthracis spore outgrowth by the lantibiotic nisin. ACS Chem Biol 2011; 6(7): 744-52.
159. Rayman MK, Aris B, Hurst A. Nisin: a possible alternative or adjunct to nitrite in the preservation of meats. Appl Environ Microbiol 1981; 41(2): 375-80.
160. Brumfitt W, Salton MR, Hamilton-Miller JM. Nisin, alone and combined with peptidoglycan-modulating antibiotics: activity against methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci. J Antimicrob Chemother 2002; 50(5): 731-4.
161. Yuan J, Zhang ZZ, Chen XZ, Yang W, Huan LD. Site-directed mutagenesis of the hinge region of nisinZ and properties of nisinZ mutants. Appl Microbiol Biotechnol 2004; 64(6): 806-15.
162. Field D, Quigley L, O'Connor PM, et al. Studies with bioengineered Nisin peptides highlight the broad-spectrum potency of Nisin V. Microb Biotechnol 2010; 3(4): 473-86.
163. Shi Y, Yang X, Garg N, van der Donk WA. Production of lantipeptides in Escherichia coli. J Am Chem Soc 2011; 133(8): 2338-41.
164. Xie L, Miller LM, Chatterjee C, Averin O, Kelleher NL, van der Donk WA. Lacticin 481: in vitro reconstitution of lantibiotic synthetase activity. Science 2004; 303(5658): 679-81.
165. Levengood MR, Knerr PJ, Oman TJ, van der Donk WA. In vitro mutasynthesis of lantibiotic analogues containing nonproteinogenic amino acids. J Am Chem Soc 2009; 131(34): 12024-5.
166. Lievin-Le Moal V, Servin AL. The front line of enteric host defense against unwelcome intrusion of harmful microorganisms: mucins, antimicrobial peptides, and microbiota. Clin Microbiol Rev 2006; 19(2): 315-37.
167. Pan SJ, Cheung WL, Link AJ. Engineered gene clusters for the production of the antimicrobial peptide microcin J25. Protein Expr Purif 2010; 71(2): 200-6.
168. Pan SJ, Link AJ. Sequence diversity in the lasso peptide framework: discovery of functional microcin J25 variants with multiple amino acid substitutions. J Am Chem Soc 2011; 133(13): 5016-23.
169. Walsh CT. Polyketide and nonribosomal peptide antibiotics: modularity and versatility. Science 2004; 303(5665): 1805-10.
170. Fischbach MA, Walsh CT. Assembly-line enzymology for polyketide and nonribosomal Peptide antibiotics: logic, machinery, and mechanisms. Chem Rev 2006; 106(8): 3468-96.
171. Nolan EM, Walsh CT. How nature morphs peptide scaffolds into antibiotics. Chembiochem 2009; 10(1): 34-53.
172. Crawford JM, Portmann C, Kontnik R, Walsh CT, Clardy J. NRPS substrate promiscuity diversifies the xenematides. Org Lett 2011; 13(19): 5144-7.
173. Gonzalez-Pastor JE, Hobbs EC, Losick R. Cannibalism by sporulating bacteria. Science 2003; 301(5632): 510-3.
174. Lopez D, Fischbach MA, Chu F, Losick R, Kolter R. Structurally diverse natural products that cause potassium leakage trigger multicellularity in Bacillus subtilis. Proc Natl Acad Sci U S A 2009; 106(1): 280-5.
175. Lopez D, Vlamakis H, Losick R, Kolter R. Cannibalism enhances biofilm development in Bacillus subtilis. Mol Microbiol 2009; 74(3): 609-18.
176. Nandy SK, Bapat PM, Venkatesh KV. Sporulating bacteria prefers predation to cannibalism in mixed cultures. FEBS Lett 2007; 581(1): 151-6.
177. Liu WT, Yang YL, Xu Y, et al. Imaging mass spectrometry of intraspecies metabolic exchange revealed the cannibalistic factors of Bacillus subtilis. Proc Natl Acad Sci U S A 2010; 107(37): 16286-90.
178. Neilands JB. Siderophores: structure and function of microbial iron transport compounds. J Biol Chem 1995; 270(45): 26723-6.
179. Hider RC, Kong X. Chemistry and biology of siderophores. Nat Prod Rep 2010; 27(5): 637-57.
180. Budzikiewicz H. Siderophore-antibiotic conjugates used as trojan horses against Pseudomonas aeruginosa. Curr Top Med Chem 2001; 1(1): 73-82.
181. Thomas X, Destoumieux-Garzon D, Peduzzi J, et al. Siderophore peptide, a new type of post-translationally modified antibacterial peptide with potent activity. J Biol Chem 2004; 279(27): 28233-42.
182. Seyedsayamdost MR, Traxler MF, Zheng SL, Kolter R, Clardy J. Structure and biosynthesis of amychelin, an unusual mixed-ligand siderophore from Amycolatopsis sp. AA4. J Am Chem Soc 2011; 133(30): 11434-7.
183. Shank EA, Kolter R. New developments in microbial interspecies signaling. Curr Opin Microbiol 2009; 12(2): 205-14.
184. Romero D, Traxler MF, Lopez D, Kolter R. Antibiotics as signal molecules. Chem Rev 2011; 111(9): 5492-505.
185. Henke JM, Bassler BL. Bacterial social engagements. Trends Cell Biol 2004; 14(11): 648-56.
186. Ng WL, Bassler BL. Bacterial quorum-sensing network architectures. Annu Rev Genet 2009; 43: 197-222.
187. Holden MT, Ram Chhabra S, de Nys R, et al. Quorum-sensing cross talk: isolation and chemical characterization of cyclic dipeptides from Pseudomonas aeruginosa and other gram-negative bacteria. Mol Microbiol 1999; 33(6): 1254-66.
188. Park DK, Lee KE, Baek CH, et al. Cyclo(Phe-Pro) modulates the expression of ompU in Vibrio spp. J Bacteriol 2006; 188(6): 2214-21.
189. Mayville P, Ji G, Beavis R, et al. Structure-activity analysis of synthetic autoinducing thiolactone peptides from Staphylococcus aureus responsible for virulence. Proc Natl Acad Sci U S A 1999; 96(4): 1218-23.
190. Clatworthy AE, Pierson E, Hung DT. Targeting virulence: a new paradigm for antimicrobial therapy. Nat Chem Biol 2007; 3(9): 541-8.
191. Li J, Wang W, Xu SX, Magarvey NA, McCormick JK. Lactobacillus reuteri-produced cyclic dipeptides quench agrmediated expression of toxic shock syndrome toxin-1 in staphylococci. Proc Natl Acad Sci U S A 2011; 108(8): 3360-5.
192. Gonzalez JE, Keshavan ND. Messing with bacterial quorum sensing. Microbiol Mol Biol Rev 2006; 70(4): 859-75.
193. Fowler SA, Stacy DM, Blackwell HE. Design and synthesis of macrocyclic peptomers as mimics of a quorum sensing signal from Staphylococcus aureus. Org Lett 2008; 10(12): 2329-32.
194. Campbell J, Blackwell HE. Efficient construction of diketopiperazine macroarrays through a cyclative-cleavage strategy and their evaluation as luminescence inhibitors in the bacterial symbiont Vibrio fischeri. J Comb Chem 2009; 11(6): 1094-9.
195. Praneenararat T, Geske GD, Blackwell HE. Efficient synthesis and evaluation of quorum-sensing modulators using small molecule macroarrays. Org Lett 2009; 11(20): 4600-3.
196. Van Melderen L. Toxin-antitoxin systems: why so many, what for? Curr Opin Microbiol 2010; 13(6): 781-5.
197. Hayes F, Van Melderen L. Toxins-antitoxins: diversity, evolution and function. Crit Rev Biochem Mol Biol 2011; 46(5): 386-408.
198. Wang X, Wood TK. Toxin-antitoxin systems influence biofilm and persister cell formation and the general stress response. Appl Environ Microbiol 2011; 77(16): 5577-83.
199. Jaffe A, Ogura T, Hiraga S. Effects of the ccd function of the F plasmid on bacterial growth. J Bacteriol 1985; 163(3): 841-9.
200. Wozniak RA, Waldor MK. A toxin-antitoxin system promotes the maintenance of an integrative conjugative element. PLoS Genet 2009; 5(3): e1000439.
201. Wang X, Kim Y, Hong SH, et al. Antitoxin MqsA helps mediate the bacterial general stress response. Nat Chem Biol 2011; 7(6): 359-66.
202. Amitai S, Yassin Y, Engelberg-Kulka H. MazF-mediated cell death in Escherichia coli: a point of no return. J Bacteriol 2004; 186(24): 8295-300.
203. Rotem E, Loinger A, Ronin I, et al. Regulation of phenotypic variability by a threshold-based mechanism underlies bacterial persistence. Proc Natl Acad Sci U S A 107(28): 12541-6.
204. Lewis K. Persister cells. Annu Rev Microbiol 2011; 64: 357-72.
205. Fozo EM, Hemm MR, Storz G. Small toxic proteins and the antisense RNAs that repress them. Microbiol Mol Biol Rev 2008; 72(4): 579-89, Table of Contents.
206. Pecota DC, Osapay G, Selsted ME, Wood TK. Antimicrobial properties of the Escherichia coli R1 plasmid host killing peptide. J Biotechnol 2003; 100(1): 1-12.
207. Mok WW, Patel NH, Li Y. Decoding toxicity: deducing the sequence requirements of IbsC, a type I toxin in Escherichia coli. J Biol Chem 2010; 285(53): 41627-36.
208. Lee S, Hinz A, Bauerle E, et al. Targeting a bacterial stress response to enhance antibiotic action. Proc Natl Acad Sci U S A 2009; 106(34): 14570-5.
209. Fozo EM, Makarova KS, Shabalina SA, Yutin N, Koonin EV, Storz G. Abundance of type I toxin-antitoxin systems in bacteria: searches for new candidates and discovery of novel families. Nucleic Acids Res 2010; 38(11): 3743-59.
210. Splith K, Neundorf I. Antimicrobial peptides with cell-penetrating peptide properties and vice versa. Eur Biophys J 2011; 40(4): 387-97.
211. Sandgren S, Wittrup A, Cheng F, et al. The human antimicrobial peptide LL-37 transfers extracellular DNA plasmid to the nuclear compartment of mammalian cells via lipid rafts and proteoglycan-dependent endocytosis. J Biol Chem 2004; 279(17): 17951-6.
212. Zhang X, Oglecka K, Sandgren S, et al. Dual functions of the human antimicrobial peptide LL-37-target membrane perturbation and host cell cargo delivery. Biochim Biophys Acta 2010; 1798(12): 2201-8.
213. Horton KL, Stewart KM, Fonseca SB, Guo Q, Kelley SO. Mitochondria-penetrating peptides. Chem Biol 2008; 15(4): 375-82.
214. Kelley SO, Stewart KM, Mourtada R. Development of novel peptides for mitochondrial drug delivery: amino acids featuring delocalized lipophilic cations. Pharm Res 2011; 28(11): 2808-19.
215. Pereira MP, Kelley SO. Maximizing the therapeutic window of an antimicrobial drug by imparting mitochondrial sequestration in human cells. J Am Chem Soc 2011; 133(10): 3260-3.
216. Sugahara KN, Teesalu T, Karmali PP, et al. Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell 2009; 16(6): 510-20.
217. Sugahara KN, Teesalu T, Karmali PP, et al. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science 2010; 328(5981): 1031-5.
218. Ellington AD, Szostak JW. In vitro selection of RNA molecules that bind specific ligands. Nature 1990; 346(6287): 818-22.
219. Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990; 249(4968): 505-10.
220. Oka T, Sakamoto S, Miyoshi K, et al. Synthesis and secretion of human epidermal growth factor by Escherichia coli. Proc Natl Acad Sci U S A 1985; 82(21): 7212-6.
221. Yoon SH, Kim SK, Kim JF. Secretory production of recombinant proteins in Escherichia coli. Recent Pat Biotechnol 2010; 4(1): 23-9.
222. Zhang G, Brokx S, Weiner JH. Extracellular accumulation of recombinant proteins fused to the carrier protein YebF in Escherichia coli. Nat Biotechnol 2006; 24(1): 100-4.
223. Kindrachuk J, Jenssen H, Elliott M, et al. A novel vaccine adjuvant comprised of a synthetic innate defence regulator peptide and CpG oligonucleotide links innate and adaptive immunity. Vaccine 2009; 27(34): 4662-71.